Showing results (21-30 of 118) with videos related to

Sort By:
Pageof 12
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2012
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)Rajendar K Mittapalli, Shruthi Vaidhyanathan, Ramola Sane, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 2, 2011
pH-Dependent transport of pemetrexed by breast cancer resistance proteinLi Li, Yuk Yin Sham, Zsolt Bikadi, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 12, 2013
Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous systemRamola Sane, Sagar Agarwal, Rajendar K Mittapalli, et al.
Pharmacological Research|June 22, 2017
Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?Gautham Gampa, Shruthi Vaidhyanathan, Jann N Sarkaria, et al.
Current Pharmaceutical Design|August 11, 2011
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upSagar Agarwal, Anika M S Hartz, William F Elmquist, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 26, 2004
Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cellsYan Zhang, John D Schuetz, William F Elmquist, et al.
Chromatographia|January 11, 2014
Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution StudiesRajneet K Oberoi, Rajendar K Mittapalli, James Fisher, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 20, 2012
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastasesRajendar K Mittapalli, Shruthi Vaidhyanathan, Arkadiusz Z Dudek, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2014
Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastasesShruthi Vaidhyanathan, Rajendar K Mittapalli, Jann N Sarkaria, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated effluxHaiQing Dai, Peter Marbach, Michel Lemaire, et al.
Pageof 12